{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(1)"],"submitter":["Okubo A"],"pubmed_abstract":["<h4>Background</h4>Intrahepatic cholangiocarcinoma (ICC) is a challenging primary liver cancer with a poor prognosis, especially in unresectable cases. Traditional palliative irradiation is limited in reducing liver doses. This study aimed to evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma.<h4>Methods</h4>Between October 2011 and February 2022, 24 patients (median [range] age, 71 [41-88] years) were evaluated at our institution. Twelve patients were pathologically diagnosed with ICC. All patients underwent respiratory-gated proton beam therapy at a dose of 48-83.6 (relative biological effectiveness) in 20-38 fractions with four-dimensional computed tomography planning. The median follow-up period was 1"],"journal":["Radiation oncology (London, England)"],"pagination":["160"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11562633"],"repository":["biostudies-literature"],"pubmed_title":["Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers."],"pmcid":["PMC11562633"],"pubmed_authors":["Matsumoto S","Yamamoto K","Aoyagi H","Takamatsu S","Sasaki M","Maeda Y","Okubo A","Kobayashi S","Tatebe H","Tamamura H","Sato Y","Matsushita K","Tameshige Y","Shibata S","Asahi S","Sunagozaka H"],"additional_accession":[]},"is_claimable":false,"name":"Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers.","description":"<h4>Background</h4>Intrahepatic cholangiocarcinoma (ICC) is a challenging primary liver cancer with a poor prognosis, especially in unresectable cases. Traditional palliative irradiation is limited in reducing liver doses. This study aimed to evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma.<h4>Methods</h4>Between October 2011 and February 2022, 24 patients (median [range] age, 71 [41-88] years) were evaluated at our institution. Twelve patients were pathologically diagnosed with ICC. All patients underwent respiratory-gated proton beam therapy at a dose of 48-83.6 (relative biological effectiveness) in 20-38 fractions with four-dimensional computed tomography planning. The median follow-up period was 1","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-12T03:13:17.028Z","creation":"2025-04-06T01:44:37.487Z"},"accession":"S-EPMC11562633","cross_references":{"pubmed":["39538328"],"doi":["10.1186/s13014-024-02550-2"]}}